Elevidys Insurance Denied? Appealing Duchenne Muscular Dystrophy Gene Therapy

Elevidys (delandistrogene moxeparvovec-rokl) is a gene therapy developed by Sarepta Therapeutics for Duchenne muscular dystrophy (DMD), a progressive and fatal muscle-wasting disease caused by mutations in the dystrophin gene. The FDA granted accelerated approval for Elevidys in June 2023 for ambulatory pediatric patients ages 4–5 with DMD who have a confirmed mutation amenable to exon 51 skipping, and subsequently expanded the label in June 2024 to include all ambulatory patients 4 years and older with a DMD mutation amenable to exon 51 skipping. With a list price of approximately $3.2 million, insurance denials are common and can have irreversible consequences given DMD's progressive trajectory.

If you have received a denial for Elevidys, this guide explains the appeal process and your rights.

Why Insurers Deny Elevidys

Accelerated approval status. Elevidys received FDA Accelerated Approval — meaning it was approved based on a surrogate endpoint (micro-dystrophin protein expression) reasonably likely to predict clinical benefit, with confirmatory trials ongoing. Some insurers use accelerated approval status as justification for an "experimental" denial, despite the fact that accelerated approval is a legitimate regulatory pathway for serious diseases with unmet needs.

Age or mutation restriction disputes. Insurers may attempt to apply narrower criteria than the expanded FDA label, for example requiring patients to be within the original 4–5 age range even after the label expanded. Verify the current FDA-approved indication and ensure your appeal references the most current label.

Step therapy requirements. Some plans require patients to have used exon-skipping antisense oligonucleotide therapies (such as eteplirsen, golodirsen, or viltolarsen) before approving gene therapy. Assess whether these step therapy requirements are clinically reasonable and whether you can document prior treatment.

Not in formulary. Ultra-high-cost gene therapies may not appear on specialty formularies, leading to administrative denials separate from medical necessity determinations.

Functional status requirements. Some insurer coverage policies impose ambulatory function tests (e.g., North Star Ambulatory Assessment scores) as coverage prerequisites. If the insurer's thresholds differ from the FDA label, this can be challenged.

FDA Approval Status and Clinical Evidence

Elevidys received FDA Accelerated Approval on June 22, 2023, and the indication was expanded on June 20, 2024. It is the first systemic gene therapy approved for DMD. The approval was based on evidence of micro-dystrophin protein expression in muscle tissue, with confirmatory trials underway.

The EMBARK Phase 3 trial results, published in 2024, demonstrated improvement in functional motor outcomes measured by the North Star Ambulatory Assessment, providing additional clinical evidence supporting the therapy's benefit. Elevidys holds FDA Orphan Drug Designation, Rare Pediatric Disease Designation, Breakthrough Therapy Designation, and Priority Review.

Building Your Appeal

Neurologist letter of medical necessity. Your child's neuromuscular specialist should document the DMD diagnosis with genetic mutation characterization, current ambulatory status, rate of functional decline (motor function scores over time), and clinical rationale for gene therapy including the urgency created by the disease's progressive nature.

Genetic report confirming exon 51 skippable mutation. Include the full genetic testing report confirming the DMD mutation and its amenability to the Elevidys mechanism. This directly addresses the FDA label criteria.

EMBARK trial data. Cite the published Phase 3 results demonstrating functional improvements. Attach the study abstract or full publication to your appeal.

Accelerated approval rebuttal. Address directly any insurer characterization of Elevidys as "experimental" based on accelerated approval. The FDA's accelerated approval pathway is a legitimate approval mechanism for serious diseases — the drug is not experimental, it is approved. Cite the FDA's accelerated approval program description.

Expert DMD physician attestation. If possible, obtain a supporting letter from a DMD specialist at an academic medical center or neuromuscular disease center corroborating the treating physician's assessment.

Time-sensitivity. DMD is progressive, and the therapeutic window for gene therapy is limited to the ambulatory phase. Document explicitly that delay risks progression beyond the label criteria and loss of the treatment opportunity permanently.

Expedited Review Rights

DMD's progressive course makes timing critical. If delay of treatment risks the patient losing ambulatory function and exiting the eligible treatment window, this constitutes a clinical urgency. Request expedited internal appeal review with supporting physician documentation. Federal law requires a decision within 72 hours for urgent cases.

External Independent Review: Complete Guide" class="auto-link">External Review

External review by a qualified neuromuscular disease specialist is your right after internal appeal exhaustion. The combination of FDA approval, orphan drug designation, and published Phase 3 data makes denials based on "experimental" grounds highly vulnerable on external review.

Patient Assistance

Sarepta Therapeutics offers patient support services including insurance advocacy and financial assistance programs. Contact their patient access team immediately upon receiving a denial.

Parent Project Muscular Dystrophy (PPMD) is a leading DMD advocacy organization that provides case management support, insurance appeal guidance, and connection to DMD clinical specialists. CureDuchenne is another nonprofit with advocacy resources. NORD may provide emergency financial assistance and connects patients to disease networks.

Fight Back With ClaimBack

A denial for Elevidys is especially urgent because DMD's progression means that waiting is not neutral — it means losing function that cannot be recovered. ClaimBack helps DMD families build authoritative insurance appeals with the urgency and evidence that these cases demand.

Start your appeal now at https://claimback.app/appeal.

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs. External Insurance Appeal: Which Should You File?